Cite
HARVARD Citation
Charokopou, M. et al. (2015). Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective. BMC health services research. 15 (1), pp. 1-11. [Online].